Contract notice: Pharmaceutical products

• Country: Germany
• Summary: Contract notice: Pharmaceutical products
• DET Ref No: 36384364
• Deadline: 05 Sep 2021
• Financier: Self Financed
• Purchaser Ownership: Government
• Tender Value: Refer Document
• Notice Type: Tender
• Document Ref. No.: 435435-2019
• Purchaser's Detail:
  Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.

  Login to see details
• Description:
• Object of the contract
  Pharmaceutical products
  
  Description: Contract notice: Pharmaceutical products
  
  Authority Type: Body governed by public law
  Contact Nature: Supplies
  Procedure: Open procedure
  Document: Contract notice
  Regulation: European Union
  Award criteria: Lowest price
  CPV code: 33600000,33600000
  CPV Description: Pharmaceutical products.
  Conclusion of a non-exclusive discount agreement pursuant to Section 130a (8) SGB V on the active substance piroxicam, ATC M01AC01, for the period 1.11.2019 31.10.2021
  Reference Number: 1002729 - Piroxicam, ATC M01AC01
  Section 130a (8) SGB V allows the health insurance companies and pharmaceutical companies, framework discount contracts on the to be paid to the statutory health insurance Aclose the drug. In view of the pertinent legal regulations for the awarding of public contracts, a regular process of active substance-related, public procurement procedures takes place according to the regulations of the 4th part of the GWB by the DAK-G. For the medicinal product to be designated by the tenderer in Appendix 2 to the contract with regard to the active substance piroxicam, ATC M01AC01, beDAK-G intends to conclude drug discount agreements with as many pharmaceutical companies as possible until new drug agreements come into force. A discount contract within the scope of the approval model for the o. G. Active ingredient will enter into force on 1.11.2019 and will end on 31.10.2021. It ends automatically regardless of the entry into force of the exclusive contractDAK-Gesundheit ("DAK-G") assumes that this procedure does not fall within the scope of antitrust law due to the lack of a selection decision and thus the non-discriminatory accessibility of all pharmaceutical companies, and automatically ends when the exclusive agreement comes into force to Piroxicam, ATC M01AC01, as a result of a foermlitendering procedure in accordance with the regulations of Part 4 of the GWB with one or more contractual partners. In order to meet the diversity of potential contractors within the scope of the approval model, each pharmaceutical company will be able to conclude a framework contract at any time and under the same conditions during the contract period. The required for this contractApplication documents are available for download via the online portal www.dtvp.de/center under the link named under I.3).
  Requirements for the conclusion or later accession to the contracts which enter into force on 1.11.2019 is the complete and timely transmission of the following proofs / statements / attachments (available for download under I.3)1 link);
  2) Current proof of entry in the professional or commercial register (see III.1.1.);
  3) Self-declaration by the company (Annex A1 ), that none of the exclusion criteria according to -- 123, 124 GWB is present (see III.1.1.); 4) self-declaration that for those medicines for which the interested partyto conclude a contract under this procedure, to have a drug license and that the bidder is entitled to distribution at the beginning of the contract (Appendix A2) (see III.1.1.); 5) self - declaration by the company that the legal minimum wage requirements and adherence to tariff fidelity (Annex A3) (see III.1.1.);
  6) recognition of contractual obligationsDAK-G stipulations, in particular also the prescribed discounts by signing the contract stamped with a company stamp (twice in the original) by the interested party at the designated place;
  7) Attachments 1 and 2 to the contract (twice each in the Original). The interested party has the medicines for the o.g. To enter active substances which are to become subject of the contract;
  8) Effective PrAcknowledgment of DAK-G (see III.1.1 and III.1.2.)
  The documents must be submitted by post to:
  DAK-Health
  Henri Affinass (0032 00)
  Nagelsweg 27-31
  20097 Hamburg
  Continue is the attachment 2 as an Excel file at the same time to the mail address am_rabattvertraege@dak.de to send. Contracts under this model and to o. G. The active ingredient will be used for the first time with effect from 1.11.2019 completed and ended on 31.10.2021. Interested parties who want to become contract partners for this date, have the o. G. Documents until the 5th of the previous month at o. G. Submit job. It depends on the timely access to the DAK-G. For the deadline is an electronic receipt of the complete documents to the above. E-mail address is sufficient. Later accessionsare possible at any time. In order to be able to join during the term of the contract on the 1st or 15th of the following month, the o. G. Documents, regardless of the desired accession, the DAK-G are available until the 5th of the previous month. Example: The applicant`s desired joining should take place on 15.07.20xx (following month), the documents would have to be available until 05.06.20xx (previous month).
  Note:the publication is done here using the Open Procedure form. As has already been made clear, this is not such a notice had to be used for technical reasons, as there is no form suitable for registration procedures.
  1) Current proof of registration in the professional or commercial register (not older than 6 months at Vein accordance with the legislation of the country in which the company is established, eg Eg current commercial register extract; Copy is sufficient;
  2) Self-declaration by the company that none of the exclusion criteria according to -- 123, 124 GWB exists. Attachment A1 has to be signed, stamped with company stamp and submitted in the original;
  3) Self-declaration about it, thes for those medicines for which the prospective buyer wishes to conclude a contract under this procedure, a drug license and that the tenderer is entitled to sell at the inception of the contract (Appendix A2) (see III.1.1.); Company that the legal requirements for minimum wage and tariff fidelity are observed and adhered to (Anlage A3). Attachment A3 should be signed, stamped with a company seal and submitted in original form.
  DAK-Gesundheit has published a so-called pre-qualification procedure for pharmaceutical companies for the simplified participation in future drug rebate tenders via the European Announcement Platform (EU Announcement 2015 / S 105 -190319 from 3.6.2015), If the bidder has received an effective pre-qualification notification from DAK-Gesundheit in good time before submission of the documents, he needs the company-specific proof of suitability (proof of entry in the trade or professional register, self-declaration by the company that none of the exclusion criteria according to -- 123, 124 GWB is present, clearance certificate of the gesehealth insurance, self-declaration minimum wage and tariff fidelity) under reference and enclosing the Praequalifikationsbescheides in copy no longer to be attached. Attachment A2 must always be attached. Accordingly, the DAK health prenqualification notification also serves as proof of DAK health open-house procedures, regardless of the value of the order.
  Self-declaration thatfor those medicines for which the prospective buyer wishes to conclude the contract in the context of this procedure, a drug license exists and that the bidder is entitled to the distribution at the beginning of the contract. Attachment A2 has to be signed, stamped and submitted in original. The DAK health has over the European announcement platform a so-called pre-qualification procedure for pharmaceutical companies for simplified participation in future drug rebate tenders published (EU Announcement 2015 / S 105-190319 of 3.6.2015). If the bidder has received an effective pre-qualification notification from DAK-Gesundheit in good time before submission of the documents, he needs the company-relatedn Proof of eligibility (proof of registration in the trade or professional register, self-declaration by the company that none of the exclusion criteria according to -- 123, 124 GWB is present, certificate of health insurance from the statutory health insurance, self-declaration minimum wage and rate loyalty) under reference and enclose the Praequalifikationsbescheides in copy not to add more. The plant A2 ist in any case. The pre-qualification notification from DAK-Gesundheit also serves as proof in open-house procedures of DAK-Gesundheit.
  The tender documents can also be requested by e-mail from the contact point named under I.1) in the necessary individual case. The tender documents will then be sent by e-mail. Questions and information about the tender documentsare to be sent by e-mail or in writing (by fax or letter) to the contact point specified under I.1) by electronic means (by means of bidder communication via the procurement portal www.dtvp.de) or in necessary individual cases. They are to be formulated in German. Answers will be sent to all entrepreneurs who have requested the tender documents by means of a registration, made accessible in anonymous form. The answers are provided to the entrepreneurs by way of bidder communication via the allocation portal www.dtvp.de. Companies who have downloaded the tender documents without registration, have to follow the further communication on their own responsibility and if necessary to the o. G. Contact point.
  At deThis publication does not constitute a public service contract within the meaning of the 2014/24 / EU Procurement Coordination Directive of the European Parliament and of the Council or of the Public Procurement Act. In order to ensure the widest possible degree of transparency for the intended conclusion of the contract, it is published in the Supplement to the Official Journal of Europaeischen union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process name "Open Procedure", are solely due to the use of this announcement form and the publication platform, another meaning, in particular a submission to procurement lawLegal regulations, unless they are legally binding, are not binding.
  Announcement ID: CXP4YM5DRSV
  
  Internet address (URL): www.dak.de
• Documents:

 Tender Notice